<DOC>
	<DOCNO>NCT01951755</DOCNO>
	<brief_summary>An open-label , non randomize clinical trial Tarceva single agent progress non-small cell lung cancer patient .</brief_summary>
	<brief_title>Phase IV Study Tarceva Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>An observational non randomize clinical trial Tarceva single agent progress non-small cell lung cancer patient chemotherapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological document diagnosis diagnosis inoperable , locally advanced , recurrent metastatic ( Stage IIIB IV ) NSCLC . Patients must evidence disease measurable disease mandatory . 18 year age old . ECOG Performance Status 02 . Life expectancy least 12 week . Patients advanced stage IIIB/ IV NSCLC receive least one course standard systemic chemotherapy radiation therapy investigator 's opinion medically suitable chemotherapy radiotherapy . No 2 prior chemotherapy regimens permissible . Patients must recover toxic effect least 34 week must elapse last dose prior registration ( 14 day vinorelbine vinca alkaloid gemcitabine ) . Patients , opinion investigator , fully recover surgery le 4 week may also consider study . Patients must recover ( CTC ≤ 1 ) acute toxicity previous therapy . Granulocyte count ≥ 1.5 x 109/L platelet count &gt; 100 x 109/L . Serum bilirubin must ≤ 1.5 upper limit normal ( ULN ) . AST and/or ALT ≤ 2 x ULN ( ≤ 5 x ULN clearly attributable liver metastasis . Serum creatinine ≤ 1.5 ULN creatinine clearance ≥ 60 ml/min . Able comply study followup procedure . For female childbearing potential negative pregnancy test must obtain within 72 hour start therapy . Patients reproductive potential must use effective contraception . Written ( sign ) Informed Consent participate study . Any unstable systemic disease ( include active infection , grade 4 hypertension , unstable angina , congestive heart failure , hepatic , renal metabolic disease ) . Prior therapy systemic antitumour therapy HER1/EGFR inhibitor ( small molecule monoclonal antibody therapy ) . Any malignancy within 5 year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer ) . Patients exclude brain metastasis spinal cord compression newly diagnose and/ yet definitively treat surgery and/ radiation ; previously diagnose treat CNS metastases spinal cord compression evidence stable disease ( clinically stable image ) least 2 month permit . Any significant ophthalmologic abnormality , especially severe dry eye syndrome , keratoconjunctivitis sicca , Sjogren syndrome , severe exposure keratitis disorder likely increase risk corneal epithelial lesion . The use contact lenses recommend study . The decision continue wear contact lens discuss patient 's treat Oncologist ophthalmologist . Patients take oral medication , require intravenous alimentation , prior surgical procedure affect absorption , active peptic ulcer disease . Nursing mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Inoperable NSCLC</keyword>
	<keyword>TKIs</keyword>
</DOC>